Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells.
apoptosis
arrest
bladder cancer
cell cycle
medicarpin
therapy
Journal
Acta pharmaceutica (Zagreb, Croatia)
ISSN: 1846-9558
Titre abrégé: Acta Pharm
Pays: Poland
ID NLM: 9303678
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
accepted:
06
12
2022
medline:
14
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Bladder cancer (BC) is the tenth most commonly diagnosed cancer. High recurrence, chemoresistance, and low response rate hinder the effective treatment of BC. Hence, a novel therapeutic strategy in the clinical management of BC is urgently needed. Medicarpin (MED), an isoflavone from
Identifiants
pubmed: 37307373
pii: acph-2023-0016
doi: 10.2478/acph-2023-0016
doi:
Substances chimiques
medicarpin
6TX086I6IG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-225Informations de copyright
© 2023 Yuan Chen et al., published by Sciendo.
Références
H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries , CA Cancer. J. Clin . 71 (3) (2021) 209–249; https://doi.org/10.3322/caac.21660
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , CA Cancer J. Clin . 68 (6) (2018) 394–424; https://doi.org/10.3322/caac.21492
H. Su, H. Jiang, T. Tao, X. Kang, X. Zhang, D. Kang, S. Li, C. Li, H. Wang, Z. Yang and C. Li, Hope and challenge: Precision medicine in bladder cancer , Cancer Med . 8 (4) (2019) 1806–1816; https://doi.org/10.1002/cam4.1979
S. K. Bhanvadia, Bladder cancer survivorship , Curr. Urol. Rep . 19 (12) (2018) Article ID 111; https://doi.org/10.1007/s11934-018-0860-6
M. Babjuk, M. Burger, O. Capoun, D. Cohen, E. M. Compérat, J. L. Dominguez Escrig, P. Gontero, F. Liedberg, A. Masson-Lecomte, A. H. Mostafid, J. Palou, B. W. G. van Rhijn, M. Rouprêt, S. F. Shariat, T. Seiseu, V. Soukup and R. J. Sylvester, European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) , Eur. Urol . 81 (1) (2022) 75–94; https://doi.org/10.1016/j.eururo.2021.08.010
C. Seidl, Targets for therapy of bladder cancer , Semin. Nucl. Med . 50 (2) (2020) 162–170; https://doi.org/10.1053/j.semnuclmed.2020.02.006
J. A. Witjes, H. M. Bruins, R. Cathomas, E. M. Compérat, N. C. Cowan, G. Gakis, V. Hernández, E. Linares Espinós, A. Lorch, Y. Neuzillet, M. Rouanne, G. N. Thalmann, E. Veskimäe, M. J. Ribal, A. G. van der Heijden, European Association of Urology Guidelines on Muscle-invasive and Meta-static Bladder Cancer: Summary of the 2020 Guidelines , Eur. Urol . 79 (1) (2021); https://doi.org/10.1016/j.eururo.2020.03.055
J. Bellmunt and D. P. Petrylak, New therapeutic challenges in advanced bladder cancer , Semin Oncol . 39 (5) (2012) 598–607; https://doi.org/10.1053/j.seminoncol.2012.08.007
M. D. Galsky, S. K. Pal, S. Chowdhury, L. C. Harshman, S. J. Crabb, Y.-N. Wong, E. Y. Yu, T. Powles, E. L. Moshier, S- Ladoire, S. A. Hussain, N. Agarwal, U. N. Vaishampayan, F. Recine, D. Berthold, A. Nechi, C. Theodore, M. I. Milowsky, J. Bellmunt and J. Rosenberg, Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer , Cancer 121 (15) (2015) 2586–2593; https://doi.org/10.1002/cncr.29387
H. B. Grossman, R. B. Natale, C. M. Tangen, V. O. Speights, N. J. Vogelzang, D. L. Trump, R. W. deVere White, M. F. Sarosdy, D. P. Wood. Jr, D. Raghavan and E. D. Crawford, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer , N. Engl. J. Med . 349 (9) (2003) 859–866; https://doi.org/10.1056/NEJMoa022148
C. N. Sternberg, I. Skoneczna, J. M. Kerst, P. Albers, S. D. Fossa, M. Agerbaek, H. Dumez, M. de Santis, C. Théodore, M. G. Leachy, J. D. Chester, A. Verbaeys, G. Daugaard, L. Wood, V. A. Vitjes, R. de Wit, L. Geoffrois, L. Sengelov, G. Thalmann, D. Charpentier, F. Rolland, L. Mignot, S. Sundar, P. Symonds, J. Graham, F. Joly, S. Marreaud, L. Collette and R. Sylvester, Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial , Lancet Oncol . 16 (1) (2015) 76–86; https://doi.org/10.1016/S1470-2045(14)71160-X
A. V. Balar, M. D. Galsky, J. E. Rosenberg, T. Powles, D. P. Petrylak, J. Bellmunt, Y. Loriot, A. Necchi, J. Hoffman-Censits, J. L. Perez-Gracia, N. A. Dawson, M. S. van der Heijden, R. Dreicer, S. Srinivas, M. M. Retz, R. Joseph, A. Drakaki, U. N. Vaishampayan, S. S. Gridhar, D. I. Quinn, I. Duron, D. Shaffer, B. J. Eigl, P. D. Grivas, E. Y. Yu, S. Li, E. E. Kadel III, Z. Boyd, R. Burgon, P. S. Hegde, S. Mariathasan, A. K. Thåström, O. O. Abidoye, G. D. Fine and D. F. Bajorin, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , Lancet 389 (10064) (2017) 67–76; https://doi.org/10.1016/S0140-6736(16)32455-2
M. De Santis, J. Bellmunt, G. Mead, J. M. Kerst, M. Leahy, P. Maroto, T. Gil, S. Marreaud, S. Collette, J. Lorent and R. Sylvester, Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 , J. Clin. Oncol . 30 (2) (2012) 191–199; https://doi.org/10.1200/jco.2011.37.3571
Y. Xiang, Z. Guo, P. Zhu, J. Chen and Y. Huang, Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science , Cancer Med . 8 (5) (2019) 1958–1975; https://doi.org/10.1002/cam4.2108
Y. Xia, S. Chen, J. Cui, Y. Wang, X. Liu, Y. Shen, L. Gong, X. Jiang, W. Wang, Y. Zhu, S. Sun, J. Li, Y. Zou and B. Shi, Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p , Biochem. Pharmacol . 188 (2021) Article ID 114575; https://doi.org/10.1016/j.bcp.2021.114575
W. Niu, L. Xu, J. Li, Y. Zhai, Z. Sun, W. Shi, Y. Jiang, C. Ma, H. Lin, Y. Guo and Z. Liu, Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs , Oncol. Lett . 20 (3) (2020) 2928–2936; https://doi.org/10.3892/ol.2020.11839
X.-Z. Liao, L.-T. Tao, J.-H. Liu, Y.-Y. Gu, J. Xie, Y. Chen, M.-G. Lin, T.-L. Liu, D. M. Wang, H. Y. Guo and S. L. Mo, Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway , Cancer Cell Int . 17 (2017) Article ID 124 (14 pages); https://doi.org/10.1186/s12935-017-0495-6
I. Muhammad, M. R. Jacob, M. A. Ibrahim, V. Raman, M. Kumarihamy, M. Wang, T. Al-Adhami, C. Hind, M. Clifford, B. Martin, J. Zhao, J. M. Sutton and K. M. Rahman, Antimicrobial constituents from Machaerium Pers.: Inhibitory activities and synergism of machaeriols and machaeridiols against methicillin-resistant Staphylococcus aureus , vancomycin-resistant Enterococcus faecium , and permeabilized Gram-negative pathogens , Molecules 25 (24) (2020); https://doi.org/10.3390/molecules25246000
H. Chen, X. Zhao, T. Lv, X. Qiu, L. Luo, M. Zhang, H. Yang, X. Chang, P. Li, C. L. Wu, D. Xie, Y. Quian and C. Yang, Compounds from the root of Pueraria peduncularis (Grah. ex Benth.) Benth. and their antimicrobial effects , Pest. Manag. Sci . 75 (10) (2019) 2765–2769; https://doi.org/10.1002/ps.5387
A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and S. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice , Mol. Cell. Endocrin . 325 (1-2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016
G. Gatouillat, A. A. Magid, E. Bertin, H. El Btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa , induce apoptosis and overcome multidrug resistance in leukemia P388 cells , Inter. J. Phytother. Phytopharmacol. 22 (13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005
R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROSJNK-CHOP pathway , Cell Death Disease 5 (10) (2014) Article ID e1465 (10 pages); https://doi.org/10.1038/cddis.2014.429
H. Su, T. Tao, Z. Yang, X. Kang, X. Zhang, D. Kang, S. Wu and C. Li, Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression , Mol. Cancer 18 (1) (2019) Article ID 27 (15 pages); https://doi.org/10.1186/s12943-019-0951-0
Z. Yang, C. Li, Z. Fan, H. Liu, X. Zhang, Z. Cai, L. Xu, J. Luo, Y. Huang, L. He, C. Liu and S. Wu, Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells , Eur. Urol . 71 (1) (2017) 8–12; https://doi.org/10.1016/j.eururo.2016.06.025
E. C. Jensen, Quantitative analysis of histological staining and fluorescence using ImageJ , Anat. Rec. (Hoboken) . 296 (3) (2013) 378–381; https://doi.org/10.1002/ar.22641
S. Antoni, J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal and F. Bray, Bladder cancer incidence and mortality: A global overview and recent trends , Eur. Urol . 71 (1) (2017) 96–108; https://doi.org/10.1016/j.eururo.2016.06.010
S. Cambier, R. J. Sylvester, L. Collette, P. Gontero, M. A. Brausi, G. van Andel, W. J. Kirkels, F. C. Silva, W. Oosterlinck, S. Prescott, Z. Kirkali, P. H. Powell, T. M. Reijke, L. Turkeri, S. Collette and J. Oddens, EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin , Eur. Urol . 69 (1) (2016) 60–69; https://doi.org/10.1016/j.eururo.2015.06.045
S. Wang, S. Long and W. Wu, Application of traditional chinese medicines as personalized therapy in human cancers , Am. J. Chin. Med . 46 (5) (2018) 953–970; https://doi.org/10.1142/s0192415x18500507
D. Y. Zhang, Y. B. Cheng, Q. H. Guo, X. L. Shan, F. F. Wei, F. Lu, C. S. Sheng, Q. F. Huang, C. H. Yang, Y. Li and J. G. Wang, Treatment of masked hypertension with a chinese herbal formula: a randomized, placebo-controlled trial , Circulation 142(19) (2020) 1821–1830; https://doi.org/10.1161/circulationaha.120.046685
J. Tian, D. Jin, Q. Bao, Q. Ding, H. Zhang, Z. Gao, J. Song, F. Lian and X. Tong, Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: A systematic review and meta-analysis , Diab. Obes. Metabol . 21 (8) (2019) 1801–1816; https://doi.org/10.1111/dom.13760
F. Huang, X. Zheng, X. Ma, R. Jiang, W. Zhou, S. Zhou, Y. Zhang, S. Lei, S. Wang, J. Kuang, X. Han, M. Wei, Y. You, M. Li, Y. Li, D. Liang. J. Liu, T. Chen, C. Yan, R. Wei C. Rajani, C. Shen, G. Xies, Z. Bian, H. Li, A. Zhao and W. Jia, Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism , Nature Comm . 10 (1) (2019) Article ID 4971 (17 pages); https://doi.org/10.1038/s41467-019-12896-x
K. Jiang, H. Chen, K. Tang, W. Guan, H. Zhou, X. Guo, Z. Chen, Z. Ye and H. Xu, Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway , Oncol. Lett . 15 (1) (2018) 167–174; https://doi.org/10.3892/o1.2017.7298
F. Wang, J. Tang, P. Li, S. Si, H. Yu, X. Yang, J. Tao, Q. Lv, M. Gu, H. Yang and Z. Wang, Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis , Cell Physiol. Biochem . 45 (1) (2018) 54–66; https://doi.org/10.1159/000486222
B. O’Leary, R. S. Finn and N. C. Turner, Treating cancer with selective CDK4/6 inhibitors , Nat. Rev. Clin. Oncol . 13 (7) (2016) 417–430; https://doi.org/10.1038/nrclinonc.2016.26
F. Zhao, O. Vakhrusheva, S. D. Markowitsch, K. S. Slade, I. Tsaur, J. Cinatl, Jr., M. Michaelis, T. Efferth, A. Haferkamf and E. Juengel, Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction , Cells . 9 (12) (2020) Article ID 2643 (19 pages); https://doi.org/10.3390/cells9122643
R. M. Mohammad, I. Muqbil, L. Lowe, C. Yedjou, H. Y. Hsu, L. T. Lin, M. D. Siegelin, C. Fimognari, N. B. Kumar, Q. P. Dou, H. Yang, A. K. Samadi, G. L. Russo, C. Spagnuolo, S. K. Ray, M. Chakrabarti, J. D. Morre, H. M. Coley, H. Fuji and A. S. Azmi, Broad targeting of resistance to apoptosis in cancer , Sem. Cancer Biol. 35 Suppl (0) (2015) S78–103; https://doi.org/10.1016/j.semcancer.2015.03.001
R. S. Wong, Apoptosis in cancer: from pathogenesis to treatment , J. Exp. Clin. Cancer Res. 30 (1) (2011) Article ID 87 (14 pages); https://doi.org/10.1186/1756-9966-30-87
B. A. Carneiro and W. S. El-Deiry, Targeting apoptosis in cancer therapy , Nat. Rev. Clin. Oncol . 17 (7) (2020) 395–417; https://doi.org/10.1038/s41571-020-0341-y